Difference between revisions of "Team:ASIJ TOKYO/Description"

Line 171: Line 171:
 
</div>
 
</div>
  
−
<!-- Three -->
+
<!-- Four -->
−
<section id="three" class="wrapper spotlight style3">
+
<section id="four" class="wrapper alt style1">
−
<div class="inner">
+
<div class="inner">
−
<div class="content">
+
<h2 class="major">Figures</h2>
−
<h2 class="major">Project Motivations</h2>
+
<section class="features">
−
<p>After speaking to Minako Abe, an immunologist, we became aware of the immense prevalence and impact--especially in Japan--of colorectal cancer. In Japan alone, in 2015, there were almost 50,000 deaths from colorectal cancer, marking a sudden, sharp spike in the number of young adults that were diagnosed with this cancer. Finding out that two faculty members at our school were survivors of this disease further cemented our belief in the importance of addressing it at its root.
+
<article>
−
The issue is especially prevalent in Japan mostly because the younger generation is not fully aware on how common colorectal cancer is becoming and because they are not checking up on their bodies as frequently as they should be. This motivated us to not limit our project on only addressing early detection of CRC, but also raising awareness.</p>
+
<a href="#" class="image"><https://static.igem.org/mediawiki/2017/0/03/Diagram_Models_%283%29.jpg" title="Click to return back to the top." /></a>
−
</div>
+
<h3 class="major">Figure 1: </h3>
−
</div>
+
<p>Our gene production construct is modeled to produce COX-2 and c-Myc, which we used to simulate conditions in human bodies when these proteins are overproduced, in the case of CRC. The construct consists of an Anderson promoter, a ribosomal binding site, a COX-2 gene/c-Myc gene, and a terminator</p>
−
<!-- Three -->
+
</article>
−
<section id="three" class="wrapper spotlight style3">
+
<article>
−
<div class="inner">
+
<a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/8/85/Diagram_Models_%281%29.jpg" title="Click to return back to the top." /></a>
−
<div class="content">
+
<h3 class="major">Figure 2</h3>
−
<h2 class="major">How did we do it?</h2>
+
<p> Our promoter-reporter construct is built so that only when there is both COX-2 and c-Myc will the binding sites be able to come together and glow with the addition of rapamycin. The construct built to bind with COX-2 consists of a COX-2 promoter, FKBP, c-Luc, and terminator. The construct built to bind with c-Myc consists of a c-Myc promoter, FRB, n-Luc, and terminator. </p>
−
<p>Our goal was to create a biosensor that would be able to diagnose CRC at an earlier stage and have it fit for a home-kit where use would be accessible and convenient. To do so, we looked upstream fill in. The activation of the Wnt pathway inhibits the degradation of beta-catenin, a protein that triggers the mutation of oncogenes and tumor suppressor genes. Building off of a rapamycin induced split-luciferase system characterized by the 2015 Peking iGEM team, our construct consists of a promoter reporter system that looks at two downstream products, C-myc and COX-2.
+
</article>
−
As for community outreach, we wanted to take advantage of the fact that we live in the most metropolitan area in Japan. We did so by carrying out our project mainly in Harajuku, which is one of the most popular areas in Tokyo. As ASIJ is also central to many international communities, we’ve also promoted our project at family events held at ASIJ, as well as through our virtual pre-medical club where we were able to interact with schools around the globe.</p> </div>
+
<article>
−
</div>
+
<a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/d/dc/Diagram_Models" title="Click to return back to the top." /></a>
 +
<h3 class="major">Figure 3</h3>
 +
<p> : Our promoter-reporter system consists of two separate constructs each with a gene-specific promoter attached to a non-specific binding site fused to a domain of split luciferase. One construct consists of a COX-2 promoter, a FKBP domain, and c-Luc, and the other consists of a c-Myc promoter, a FRB domain, and n-Luc. The split system is built so that only when the presence of both COX-2 and c-Myc is detected will the binding sites be able to come together with the addition of rapamycin and cause glowing. </p>
 +
</article>
 +
<article>
 +
<a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/3/3a/Diagram_Models_%282%29.jpg" title="Click to return back to the top." /></a>
 +
<h3 class="major">Figure 4</h3>
 +
<p>In solution, our two gene constructs are able to simulate the conditions in the human body by producing proteins COX-2 and c-Myc. These proteins then interact with the promoter-reporter constructs by connecting to the non- specific binding sites, allowing the dimerization of the FKBP-Rapamycin-FRB complex. This then orients the split- luciferase so they can come together.</p>
 +
</article>
 +
</section>
 +
</div>
 +
</section>
  
−
 
−
<section id="four" class="wrapper alt style1">
 
−
<div class="inner">
 
−
<a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/2/2a/Diagram_Models_%286%29.jpg" alt=""style="width:431px;height:100%;" /></a>
 
−
 
−
<p>Figure 1: This is an inactive Wnt pathway with no mutated genes. Here, β-catenin is degraded appropriately and does not activate transcription of Wnt genes.</p>
 
−
<a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/c/c7/PROJECT.jpg" alt=""style="width:431px;height:100%;" /></a>
 
−
 
−
<p>Figure 2: LiCl activates canonical Wnt signaling by inhibiting GSK3β-mediated phosphorylation of β-catenin. The inhibition of GSK3β activity prevents β-catenin degradation in the ubiquitin dependent proteasome pathway and leads β-catenin to enter the nucleus and interact with LEF/TCF family proteins to activate Wnt target genes. Without Wnt signalling, LKB1 serves as a binding partner for APC, recruits the APC/β-catenin destruction complex to the membrane, and inhibits Wnt signaling activity.</p>
 
−
 
−
<section class="features">
 
−
</div>
 
−
 
−
</section>
 
−
 
−
 
−
<!-- Four -->
 
−
<section id="four" class="wrapper alt style1">
 
−
<div class="inner">
 
−
<h2 class="major">Proof of Concept</h2>
 
−
<section class="features">
 
−
 
−
</div>
 
−
 
−
</section>
 
−
 
−
 
−
<!-- Three -->
 
−
<section id="three" class="wrapper alt spotlight style2">
 
−
<div class="inner">
 
−
<div class="content">
 
−
<h2 class="major">Confirmation</h2>
 
−
</div>
 
−
</div>
 
−
</section>
 
  
 
 

Revision as of 13:37, 31 October 2017

RESULTS TEMPLATE

Home
Team
Team Collaborations Attributions
Project
Description Design Experiments Notebook Results
Parts Safety Human Practices

Construct Model

Construct Model

Building off of a rapamycin induced split-luciferase system characterized by the 2015 Peking iGEM team, our construct consists of a promoter reporter system that looks at two downstream products, c-Myc and COX-2 (Peking iGEM Team 2015, 2015). These products are assembled into a construct composing of fusion proteins as well as split luciferase fragments (COX-2 - nLuc - FRB and FKBP - cLuc - c-Myc). In the presence of rapamycin, the interacting protein partners dimerize and subsequently cause luciferase to activate. In order to test this model, we created vectors of our constructs and inserted them into e-coli cells.

Figure 1: Our gene production construct is modeled to produce COX-2 and c-Myc, which we used to simulate conditions in human bodies when these proteins are overproduced, in the case of CRC. The construct consists of an Anderson promoter, a ribosomal binding site, a COX-2 gene/c-Myc gene, and a terminator.

Figure 2: Our promoter-reporter construct is built so that only when there is both COX-2 and c-Myc will the binding sites be able to come together and glow with the addition of rapamycin. The construct built to bind with COX-2 consists of a COX-2 promoter, FKBP, c-Luc, and terminator. The construct built to bind with c-Myc consists of a c-Myc promoter, FRB, n-Luc, and terminator.

Figure 3: Our promoter-reporter system consists of two separate constructs each with a gene-specific promoter attached to a non-specific binding site fused to a domain of split luciferase. One construct consists of a COX-2 promoter, a FKBP domain, and c-Luc, and the other consists of a c-Myc promoter, a FRB domain, and n-Luc. The split system is built so that only when the presence of both COX-2 and c-Myc is detected will the binding sites be able to come together with the addition of rapamycin and cause glowing.

Figure 4: In solution, our two gene constructs are able to simulate the conditions in the human body by producing proteins COX-2 and c-Myc. These proteins then interact with the promoter-reporter constructs by connecting to the non- specific binding sites, allowing the dimerization of the FKBP-Rapamycin-FRB complex. This then orients the split- luciferase so they can come together.

Figures

Figure 1:

Our gene production construct is modeled to produce COX-2 and c-Myc, which we used to simulate conditions in human bodies when these proteins are overproduced, in the case of CRC. The construct consists of an Anderson promoter, a ribosomal binding site, a COX-2 gene/c-Myc gene, and a terminator

Figure 2

Our promoter-reporter construct is built so that only when there is both COX-2 and c-Myc will the binding sites be able to come together and glow with the addition of rapamycin. The construct built to bind with COX-2 consists of a COX-2 promoter, FKBP, c-Luc, and terminator. The construct built to bind with c-Myc consists of a c-Myc promoter, FRB, n-Luc, and terminator.

Figure 3

: Our promoter-reporter system consists of two separate constructs each with a gene-specific promoter attached to a non-specific binding site fused to a domain of split luciferase. One construct consists of a COX-2 promoter, a FKBP domain, and c-Luc, and the other consists of a c-Myc promoter, a FRB domain, and n-Luc. The split system is built so that only when the presence of both COX-2 and c-Myc is detected will the binding sites be able to come together with the addition of rapamycin and cause glowing.

Figure 4

In solution, our two gene constructs are able to simulate the conditions in the human body by producing proteins COX-2 and c-Myc. These proteins then interact with the promoter-reporter constructs by connecting to the non- specific binding sites, allowing the dimerization of the FKBP-Rapamycin-FRB complex. This then orients the split- luciferase so they can come together.